| Ramey Ka Yan Roppel, MD | |
|
1604 Burtner Rd Ste 2300, Natrona Heights, PA 15065-2845 | |
| (724) 226-1400 | |
| Not Available |
| Full Name | Ramey Ka Yan Roppel |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 6 Years |
| Location | 1604 Burtner Rd Ste 2300, Natrona Heights, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720576812 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD473107 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Magee Womens Hospital Of Upmc Health System | Pittsburgh, PA | Hospital |
| Upmc St Margaret | Pittsburgh, PA | Hospital |
| Allegheny Valley Hospital | Natrona, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Upmc Community Medicine Inc | 2062318975 | 690 |
News Archive
A recent study from Scandinavia shows that the well-known differences between individuals in the efficiency of converting energy stored in food to work done by muscles are related to muscle fibre type composition and to the content of specific molecules in muscle.
A report, Antibacterial agents in clinical development - an analysis of the antibacterial clinical development pipeline, including tuberculosis, launched today by WHO shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance.
Alcohol and cannabis use during adolescence is a well-known risk factor for alcohol use disorder (AUD) and cannabis use disorder (CUD) during adulthood.
ViroStatics, a US/Italian biopharmaceutical company developing innovative immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data from a randomized, dose-ranging trial of VS411, the Company's novel combination product for treating HIV/AIDS, during the XVII International AIDS Conference this week in Vienna, Austria.
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the peer-reviewed publication of the primary outcome results of the Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy (MINDACT) clinical trial in the prestigious New England Journal of Medicine (NEJM). (i, iii, iv) The publication demonstrates that 46% of breast cancer patients considered for chemotherapy, whose tumors are classified MammaPrint Low Risk, have excellent survival without chemotherapy, and can thus be candidates to avoid this toxic therapy.
› Verified 6 days ago
| Entity Name | Upmc Community Medicine Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558976092 PECOS PAC ID: 2062318975 Enrollment ID: O20040217000388 |
News Archive
A recent study from Scandinavia shows that the well-known differences between individuals in the efficiency of converting energy stored in food to work done by muscles are related to muscle fibre type composition and to the content of specific molecules in muscle.
A report, Antibacterial agents in clinical development - an analysis of the antibacterial clinical development pipeline, including tuberculosis, launched today by WHO shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance.
Alcohol and cannabis use during adolescence is a well-known risk factor for alcohol use disorder (AUD) and cannabis use disorder (CUD) during adulthood.
ViroStatics, a US/Italian biopharmaceutical company developing innovative immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data from a randomized, dose-ranging trial of VS411, the Company's novel combination product for treating HIV/AIDS, during the XVII International AIDS Conference this week in Vienna, Austria.
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the peer-reviewed publication of the primary outcome results of the Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy (MINDACT) clinical trial in the prestigious New England Journal of Medicine (NEJM). (i, iii, iv) The publication demonstrates that 46% of breast cancer patients considered for chemotherapy, whose tumors are classified MammaPrint Low Risk, have excellent survival without chemotherapy, and can thus be candidates to avoid this toxic therapy.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ramey Ka Yan Roppel, MD 1604 Burtner Rd Ste 2300, Natrona Heights, PA 15065-2845 Ph: (724) 226-1400 | Ramey Ka Yan Roppel, MD 1604 Burtner Rd Ste 2300, Natrona Heights, PA 15065-2845 Ph: (724) 226-1400 |
News Archive
A recent study from Scandinavia shows that the well-known differences between individuals in the efficiency of converting energy stored in food to work done by muscles are related to muscle fibre type composition and to the content of specific molecules in muscle.
A report, Antibacterial agents in clinical development - an analysis of the antibacterial clinical development pipeline, including tuberculosis, launched today by WHO shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance.
Alcohol and cannabis use during adolescence is a well-known risk factor for alcohol use disorder (AUD) and cannabis use disorder (CUD) during adulthood.
ViroStatics, a US/Italian biopharmaceutical company developing innovative immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data from a randomized, dose-ranging trial of VS411, the Company's novel combination product for treating HIV/AIDS, during the XVII International AIDS Conference this week in Vienna, Austria.
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the peer-reviewed publication of the primary outcome results of the Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy (MINDACT) clinical trial in the prestigious New England Journal of Medicine (NEJM). (i, iii, iv) The publication demonstrates that 46% of breast cancer patients considered for chemotherapy, whose tumors are classified MammaPrint Low Risk, have excellent survival without chemotherapy, and can thus be candidates to avoid this toxic therapy.
› Verified 6 days ago
Matthew Vasil, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1604 Burtner Rd Ste 2300, Natrona Heights, PA 15065 Phone: 724-226-1400 | |
Elaine B Scott, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1301 Carlisle St, Natrona Heights, PA 15065 Phone: 724-226-7330 Fax: 724-226-7150 | |
Jeffrey Lineman, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1604 Burtner Rd Ste 2300, Suite 2300, Natrona Heights, PA 15065 Phone: 724-226-1400 | |
Benjamin Carnahan, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1604 Burtner Rd Ste 2300, Natrona Heights, PA 15065 Phone: 724-226-1400 | |
Dr. Vincent Bolisay Vargas, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1719 Union Ave Ste A, Natrona Heights, PA 15065 Phone: 724-226-2128 Fax: 724-226-2498 | |
Dr. Kaleigh Spencer, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1604 Burtner Rd Ste 2300, Natrona Heights, PA 15065 Phone: 724-226-1400 | |
Luke Jesser, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1604 Burtner Rd Ste 2300, Suite 2300, Natrona Heights, PA 15065 Phone: 724-226-1400 |